Umar Hayat, Ph.D. is VP of CMC and Supply Chain at Union Therapeutics and has more than two decades of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa (acquired by Galenica for 1.52B US$), Anacor (acquired by Pfizer for 5.2B US$) and Transcept Pharmaceuticals (revers merger with Paratek). He played a pivotal role in the development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis. Dr. Hayat is managing partner of Revive Pharm USA. He is also a co-founder of U&D Pharma and working on Replyte Gel, a treatment for anogenital warts. Dr. Hayat received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada. He received M.Sc. Chemistry degree from Punjab University, Institute of Chemistry

Dr Mishra (Ex Genentech, Ex NCI, Ex NIH) is the founding president and CEO of the American
Association for Precision Medicine ( and chair of ACT AAPM’s Coronavirus Taskforce He
is leading research efforts focused on preventing curing chronic diseases not only treating
the sick but also providing knowledge/tools to individuals to live longer, healthier lives

He is also the founder and CEO of Agility Pharmaceuticals, a pharmaceutical company
committed to revolutionizing drug discovery development through technology, big data,
robotics, and artificial intelligence He is a serial entrepreneur who founded his first company
after graduating high school, and his second company during his Ph D Since then, he has
accumulated a wealth of experience by building, investing, and advising numerous other
companies He is an investor, co founder/ board member of a few corporations, focused on
accelerating drug discovery/ development, data analytics, robotics, mental health, and digital
health He is also the founder of AAPM Angels and Investors AAi an investment group focused
on investing in drug discovery, diagnostics, precision medicine, technology healthcare
companies He is also the founding investor and advisor to Barcelona Ventures and serves as an
advisor to a 100 M private equity fund

Widely recognized as a thought leader in the field of ‘technology and healthcare’, Dr Mishra has
keynoted, chaired, curated, and organized numerous successful international conferences He
served as a Scientist and Principal Investigator at the pharma giant Genentech, Roche Where
he participated in several drug discovery project teams Moreover, his passion for drug
development and precision medicine has led to the identification of new drug targets,
biomarkers, companion diagnostics, and several drugs/ combinations in the clinic

His research work has been recognized globally by over 40 prestigious awards and honors Due
to his unique perspective selfless service, he is a highly respected sought after mentor to
many The companies that he has advised have raised multimillion dollars Notably, he serves
as a mentor and advisor to several VC funds and startup accelerators, including IndieBio
HIMSS/Health 2 0 ’s Project Zygote, MedLabs ZGC Capital, J&J JLabs UCSF Innovation Venture,
UCSF Invent Fund, and California Life Sciences’s FAST program, to help grow California’s life
sciences innovation ecosystem

Experienced Clinical Research Scientist with 20+ years of experience in pharmaceutical drug discovery and development in CRO and industry settings. Most recent clinical development experience in multiple sclerosis space leading to the successful marketing authorization of Zeposia (ozanimod) in the US and Europe. Therapeutic areas: Dermatology, Gastroenterology, Immunology/Inflammation, Neurology, and Oncology (Hematology and Solid Tumors).

Elise Brownell, PhD. has spent the last 35 years in the bio/pharmaceutical arena where she has played key roles in Discovery, Development and Opportunity Assessment to drive innovation.

After completing her doctorate at Yale University, Elise’s career started at SUNY Stony Brook. She continued her interest in comparative molecular biology during her tenure at Frederick Cancer Research Facility and expanded her facility with molecular genetics while in various functions at Bayer Healthcare. Her efforts were widely recognized by promotion to Director, Project Management, where she led global cross-functional teams. Elise also became a member of the founding team of a venture-backed spin out (Aerovance, Inc), where she became head of project management.

Dr. Brownell serves in Interim Executive capacities for a number of emergent and highly innovative companies in the Life Science sector, and as a mentor to the entrepreneurs who run them.

Elise received her MS, MPhil and PhD from Yale University, and her BS from Allegheny College

Iris Sison is the Director, Head of Clinical Operations at IGM Biosciences, Inc. She has over 15 years of experience with a variety of leadership and technical roles from the site level, CRO to big and small biotech settings. She has experience in clinical trial management across therapeutic areas in Phase I-IV with a strong emphasis on Phase I oncology in Solid Tumors and Hematology Oncology. Iris has led numerous study teams in operationalizing complex multicenter global studies through innovative study design and development. Over the course of her career, she has played a key role in the development of a number of successful new drugs to market e.g. Avastin, Lucentis, Herceptin, Zelboraf, Keytruda, and Ibrance.

Her experience at the site level, CRO and clinical trial management gives her a unique perspective and knowledge for patients, sites and CROs. This insight gives her an understanding of the operational challenges that would need to be managed efficiently and effectively in order to conduct a successful multi-centered global clinical trial. Iris is very passionate about delivering high quality results and continue to strive to be innovative in order to improve the speed and efficiency of drug development and eventually treat and find cures for patients with cancer and other debilitating diseases.

Laura currently serves as Vice President and Therapeutic Unit Head for Hematology and Oncology at PPD, part of Thermo Fisher Scientific. In this role she holds responsibilities for the strategic direction, business operations, and operational delivery for hematology and oncology Ph I-III clinical trials.

Laura brings with her more than 25 years from the pharma and biotech side with broad multinational experience across the product development lifecycle which includes global development, clinical operations, medical affairs, and value and access. Laura is passionate about improving the patient experience on clinical trials and delivering medicines in the most accessible ways.

Julie Martin - CEO & co-Owner joined Scimega 9 years ago. Having worked for 2 other CROs before, her passion for Scimega’s business and team stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most. As CEO, Julie’s vision is to secure the company’s long-term success by leveraging her in-depth industry expertise & business acumen. She equates that success with setting a clear vision for the organization’s continued sense of purpose. Her leadership & collaboration with the managing Board of Directors combined ensure the business excellence upon which Scimega has built its reputation. Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development.

As a Solutions Consultant with eClinical Solutions, Dan serves as a subject matter expert for the elluminate Clinical Data Cloud, the foundation of digital trials. Dan is responsible for presenting the robust data management solutions made possible with elluminate, and can customize product demonstrations to address specific customer needs.

Harit Nandani has 12+ years of experience in clinical trials data and technology leadership for both diagnostics and therapeutic trials. He specializes in clinical trial data management and analysis, configuring systems for population-scale studies, and using analytics tools to monitor projects. Currently, he is the Director of Clinical Data Management at GRAIL, overseeing data and systems for trials in the UK and US supporting early cancer detection diagnostics development. He has worked on projects enrolling over 300,000 participants, leading to the development of the Galleri test, which has detected over 50 types of cancer and has been named one of TIME Magazine's best inventions and The Atlantic's 10 most promising breakthroughs of 2022. Prior to GRAIL, Harit led late-stage pivotal trials in Oncology at Gilead Sciences and worked in various clinical research roles at a CRO and a small biopharmaceutical development company.

Sarah R. Anderson is an Executive Director, Oncology Strategy Lead at Worldwide Clinical Trials.  Ms. Anderson has dedicated the past 17 years to building and advancing innovative oncology clinical trial concepts through development execution. Her passion is leading therapeutic strategy development along with a strategic thoughtfulness on advancing clinical trial options to patients in a local community setting.